Brief: Kyverna Therapeutics Says Phase 3 Enrollment For Kysa-6 Trial To Start By Year-End
15/09/2025 18:31
Sept 15 (Reuters) - Kyverna Therapeutics Inc KYTX.O: KYVERNA THERAPEUTICS INC - PHASE 3 ENROLLMENT FOR KYSA-6 TRIAL TO START BY YEAR-END 2025 Source text: ID:nGNX7smRX3 Further company coverage: KYTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kyverna Therapeutics
See all newsHealth Rounds: Appendix removal linked with lower colon cancer risk in study
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
U.S. STOCKS ON THE MOVE-Everpure, Dropbox, Darden Restaurants